Inspiration Biopharmaceuticals Inc. reached a deal to sell its second development-stage hemophilia drug at auction Tuesday to Cangene Corp. for $5.9 million in cash upfront plus royalties and milestone payments worth $50 million.
Cangene expects the sale, which still requires bankruptcy-court approval, to close by Feb. 15, it said in a news release.
Click here for the article.